SI3378479T1 - Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol - Google Patents

Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol

Info

Publication number
SI3378479T1
SI3378479T1 SI201730345T SI201730345T SI3378479T1 SI 3378479 T1 SI3378479 T1 SI 3378479T1 SI 201730345 T SI201730345 T SI 201730345T SI 201730345 T SI201730345 T SI 201730345T SI 3378479 T1 SI3378479 T1 SI 3378479T1
Authority
SI
Slovenia
Prior art keywords
salt
pharmaceutical composition
preparing pharmaceutical
quinoline derivative
quinoline
Prior art date
Application number
SI201730345T
Other languages
English (en)
Inventor
Yun Lu
Xinhua Zhang
Chenyang Wang
Original Assignee
Jiangsu Hengrui Medicine Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co., Ltd. filed Critical Jiangsu Hengrui Medicine Co., Ltd.
Publication of SI3378479T1 publication Critical patent/SI3378479T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201730345T 2016-01-27 2017-01-23 Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol SI3378479T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610057228 2016-01-27
PCT/CN2017/072156 WO2017129088A1 (zh) 2016-01-27 2017-01-23 一种含有喹啉衍生物或其盐的药物组合物的制备方法
EP17743703.5A EP3378479B1 (en) 2016-01-27 2017-01-23 Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof

Publications (1)

Publication Number Publication Date
SI3378479T1 true SI3378479T1 (sl) 2020-10-30

Family

ID=59397365

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730345T SI3378479T1 (sl) 2016-01-27 2017-01-23 Postopek za pripravo farmacevtskega sestavka, ki obsega derivat kinolina ali njegovo sol

Country Status (23)

Country Link
US (1) US10722469B2 (sl)
EP (1) EP3378479B1 (sl)
JP (1) JP6937308B2 (sl)
KR (1) KR20180103090A (sl)
CN (2) CN107405345A (sl)
AU (1) AU2017211737B2 (sl)
BR (1) BR112018014544A2 (sl)
CA (1) CA3008701A1 (sl)
CY (1) CY1123149T1 (sl)
DK (1) DK3378479T3 (sl)
ES (1) ES2811031T3 (sl)
HK (1) HK1243357A1 (sl)
HR (1) HRP20201155T1 (sl)
HU (1) HUE050255T2 (sl)
LT (1) LT3378479T (sl)
MX (1) MX2018008862A (sl)
PL (1) PL3378479T3 (sl)
PT (1) PT3378479T (sl)
RS (1) RS60747B1 (sl)
RU (1) RU2735807C2 (sl)
SI (1) SI3378479T1 (sl)
TW (1) TWI720115B (sl)
WO (1) WO2017129088A1 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700086B (zh) * 2017-10-24 2020-08-01 大陸商江蘇恒瑞醫藥股份有限公司 一種含有喹啉衍生物的藥物組合物
KR102511672B1 (ko) * 2018-03-23 2023-03-17 우시 상량 바이오테크놀로지 씨오., 엘티디. 의약 조성물, 그 제조방법 및 사용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2283651C2 (ru) * 2001-12-21 2006-09-20 Пфайзер Продактс Инк. Способы мокрой грануляции азитромицина
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
CN101824029A (zh) * 2009-03-05 2010-09-08 厦门艾德生物医药科技有限公司 酪氨酸激酶不可逆抑制剂、其药物组合物及其用途
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
US9676746B2 (en) * 2015-01-30 2017-06-13 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22Cl2N4O2

Also Published As

Publication number Publication date
RU2018128416A3 (sl) 2020-04-21
HUE050255T2 (hu) 2020-11-30
DK3378479T3 (da) 2020-08-03
JP2019503373A (ja) 2019-02-07
CN108938586A (zh) 2018-12-07
TW201726138A (zh) 2017-08-01
PL3378479T3 (pl) 2020-11-02
EP3378479A1 (en) 2018-09-26
EP3378479A4 (en) 2018-12-19
US10722469B2 (en) 2020-07-28
US20190054025A1 (en) 2019-02-21
CY1123149T1 (el) 2021-10-29
PT3378479T (pt) 2020-07-20
AU2017211737B2 (en) 2022-04-28
CN108938586B (zh) 2021-05-14
JP6937308B2 (ja) 2021-09-22
ES2811031T3 (es) 2021-03-10
RS60747B1 (sr) 2020-10-30
CA3008701A1 (en) 2017-08-03
CN107405345A (zh) 2017-11-28
HRP20201155T1 (hr) 2020-10-30
LT3378479T (lt) 2020-09-10
TWI720115B (zh) 2021-03-01
RU2735807C2 (ru) 2020-11-09
EP3378479B1 (en) 2020-06-17
HK1243357A1 (zh) 2018-07-13
MX2018008862A (es) 2018-09-07
WO2017129088A1 (zh) 2017-08-03
RU2018128416A (ru) 2020-02-27
AU2017211737A1 (en) 2018-08-02
BR112018014544A2 (pt) 2018-12-11
KR20180103090A (ko) 2018-09-18

Similar Documents

Publication Publication Date Title
HK1231377A1 (zh) 包含喹啉衍生物或其鹽的藥物組合物及其製備方法
ZA201708663B (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
PT3339294T (pt) Derivado de quinolona, sal farmaceuticamente aceitável ou estereoisómero do mesmo como inibidor de axl
PT3429998T (pt) Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais
EP3733648A4 (en) PROCESS FOR THE MANUFACTURING OF 5R-BENZYLOXYAMINOPIPERIDINE-2S-CARBONIC ACID OR DERIVATIVE THEREOF
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
HK1243357A1 (zh) 一種含有喹啉衍生物或其鹽的藥物組合物的製備方法
ZA201908090B (en) Pharmaceutical composition and method for preparing same
SI3250188T1 (sl) Farmacevtski sestavek, ki obsega aprepitant in postopek za njegovo pripravo
HK1243351A1 (zh) 一種含有吡啶並嘧啶類衍生物或其可藥用鹽的藥物組合物
IL253946A0 (en) A method for suppressing the bitterness of quinoline histories
HK1243358B (zh) 一種含有喹啉衍生物或其鹽的藥物組合物
IL271512B (en) A method for the preparation of modified 4-aminoindan derivatives
HK1244703A1 (zh) 一種含有咪唑啉類衍生物的藥物組合物
PL3632917T3 (pl) Sposób wytwarzania pochodnych heterocyklicznych
SI3397630T1 (sl) Postoek za pripravo natrijevega pantoprazolata seskvihidrata
ZA201400446B (en) Pharmaceutical composition comprising aripiprazole or salt thereof
AU2016900064A0 (en) Processes for preparing 8-hydroxy quinoline derivatives
AU2015900040A0 (en) Processes for preparing 8-hydroxy quinoline derivatives
HUP1400520A2 (hu) Gyógyászati készítmény elõállítására alkalmazható laquinimod sók
AU2014900040A0 (en) Processes for preparing 8-hydroxy quinoline derivatives